logo-loader
viewIQ-AI Limited

IQ-AI's Imaging Biometrics developing technology that could 'revolutionise brain tumour imaging'

Michael Schmainda, co-founder and CEO of IQ-AI Limited's (LON:IQAI) subsidiary Imaging Biometrics tells Proactive London's Andrew Scott they're developing a technology that could revolutionise the detection and treatment of brain tumours. IB CAD has been created to pick up cancer cells before they are visible on standard imaging. It does this by combining multi-parameter magnetic resonance data and artificial intelligence algorithms, and, in a structured way, it can pick up the tell-tale signs of the disease.

Quick facts: IQ-AI Limited

Price: 4.85 GBX

LSE:IQAI
Market: LSE
Market Cap: £7.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: Steady FTSE 100 shrugs off second wave spike fears

Headlines from the Proactive UK newsroom. The FTSE 100’s daily switchback ride continued as it rallied again after a weak start on renewed coronavirus fears. The blue-chip index added 20 points to 6,069. After the latest lockdown easing, The Gym Group PLC (LON:GYM) said it will reopen 160...

on 10/7/20

2 min read